{"entity":{"id":"nct05565378","kind":"trial","name":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Pembrolizumab and Dostarlimab in non-small-cell lung cancer, run by GlaxoSmithKline, active and no longer recruiting.","summary":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer is a phase 2 interventional study registered as NCT05565378 by GlaxoSmithKline, with 351 participants enrolled, started 2022-10-14 and due to reach its primary completion in 2026-11-09. Interventions recorded: Pembrolizumab, Dostarlimab, Belrestotug and Nelistotug.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05565378","url":"https://clinicaltrials.gov/study/NCT05565378"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","dostarlimab"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05565378","phase":"2","setting":"A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer","sponsor":"GlaxoSmithKline","participation":[{"nct":"NCT05565378","source":"https://clinicaltrials.gov/study/NCT05565378","fetchedAt":"2026-10-07T16:53:46.156Z","studySha256":"92215fb9058a5d59d9727d901534d8b5c896d05f9c7fd58c0a8543d50cb51ef6","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-15","leadSponsor":"GlaxoSmithKline","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":351,"enrolmentType":"ACTUAL","siteCount":99,"recruitingSiteCount":0,"countries":["Argentina","Belgium","Brazil","Finland","France","Germany","Greece","Hungary","Italy","Japan","Mexico","Netherlands","Poland","Portugal","South Africa","South Korea","Spain","Thailand","Turkey (Türkiye)","United Arab Emirates","United Kingdom","United States"]}],"started":"2022-10-14","startedType":"actual","enrolled":351,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05565378/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}